Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra
Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar ...
BioWorld4d
Roche describes new SARM1 inhibitors for neurodegenerative disorders
Researchers from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have presented NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors reported to be useful for the treatment of neurodegeneration.
5 Reasons To Buy Regenxbio Right Now
Regenxbio is ranked Strong Buy due to low EV, strong partnerships, royalty income, bullish trends, and buyout potential.